Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer

Authors: Jianyi Li, Yang Zhang, Wenhai Zhang, Yang Gao, Shi Jia, Jiao Guo

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The Prognostic value of microvessel density in cancer remains unclear. Recent studies have suggested that the uneven distribution of microvessels in tumours caused the variation in sample selection which led to different prognostic outcome. The enhancement pattern of Contrast-enhanced computed tomography (CECT) is determined in part by the microvessel distribution in solid tumors. Therefore, survival analysis of tumors grouping by the enhancement pattern and the pattern of microvessel distribution is important.

Methods

Survival analysis grouped by the tumor enhancement pattern and the microvessel distribution was carried out in 255 patients with invasive ductal carcinoma.

Results

There were significant differences in overall survival (OS) and disease-free survival (DFS) among the homogeneous, heterogeneous and peripheral enhancement groups. There were significant differences between OS and DFS groups with uniform and uneven distributions of microvessels.

Conclusions

The distribution of microvessels in a tumor is a potential prognostic indicator in patients with breast cancer, and can be assessed by CECT prior the operation.
Appendix
Available only for authorised users
Literature
1.
2.
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992, 84 (24): 1875-1887. 10.1093/jnci/84.24.1875.CrossRefPubMed
3.
Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993, 143 (2): 401-409.PubMedPubMedCentral
4.
Nadkarni NJ, Geest KD, Neff T, Young BD, Bender DP, Ahmed A, Smith BJ, Button A, Goodheart MJ: Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer. Cancer Lett. 2012, doi:10.1016/j.canlet.2012.12.016
5.
Tretiakova M, Antic T, Binder D, Kocherginsky M, Liao C, Taxy JB, Oto A: Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. Hum Pathol. 2012, doi:1016/j.humpath.2012.06.009
6.
Qian CN, Huang D, Wondergem B, Teh BT: Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer. 2009, 115 (10 Suppl): 2282-9. doi:10.1002/cncr.24238CrossRefPubMed
7.
Mikalsen LT, Dhakal HP, Bruland OS, Naume B, Borgen E, Nesland JM, Olsen DR: The clinical impact of mean vessel size and solidity in breast carcinoma patients. PLoS One. 2013, 8 (10): e75954-10.1371/journal.pone.0075954. doi: 10.1371/journal.pone.0075954. eCollection 2013CrossRefPubMedPubMedCentral
8.
Tan H, Yang B, Wu J, Wana S, Gu Y, Li W, Jiang Z, Qian M, Peng W: Localization and evaluation of sentinel lymph node in breast cancer from computed tomographic lymphography. J Comput Assist Tomogr. 2011, 35 (3): 367-374. 10.1097/RCT.0b013e318213ccd9.CrossRefPubMed
9.
Hattori Y, Gabata T, Matsui O, Mochizuki K, Kitagawa H, Kayahara M, Ohta T, Nakanuma Y: Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis. World J Gastroenterol. 2009, 15 (25): 3114-21. 10.3748/wjg.15.3114.CrossRefPubMedPubMedCentral
10.
Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17 (5): 1474-81.PubMed
11.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009, 101 (10): 736-50. 10.1093/jnci/djp082.CrossRefPubMedPubMedCentral
12.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011, 22 (8): 1736-1747. 10.1093/annonc/mdr304.CrossRefPubMedPubMedCentral
13.
Akasbi Y, Bennis S, Abbass F, Znati K, Joutei KA, Amarti A, Mesbahi OE: Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez). BMC Res Notes. 2011, 4: 500-10.1186/1756-0500-4-500. doi: 10.1186/1756-0500-4-500CrossRefPubMedPubMedCentral
14.
Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO: Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer. 2011, 11: 292-10.1186/1471-2407-11-292. doi: 10.1186/1471-2407-11-292CrossRefPubMedPubMedCentral
15.
Li J, Jia S, Zhang W, Zhang Y, Fei X, Tian R: Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy. ISRN Oncol. 2013, 2013: 606398-doi: 10.1155/2013/606398. eCollection 2013PubMedPubMedCentral
16.
Monzawa S, Adachi S, Suzuki K, Hirokaga K, Takao S, Sakuma T, Hanioka K: Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT. Ann Nucl Med. 2009, 23 (10): 855-61. 10.1007/s12149-009-0314-9.CrossRefPubMed
17.
Akashi-Tanaka S, Sato N, Ohsumi S, Kimijima I, Inaji H, Teramoto S, Akiyama F: Evaluation of the usefulness of breast CT imaging in delineating tumor extent and guiding surgical management: a prospective multi-institutional study. Ann Surg. 2012, 256 (1): 157-62. 10.1097/SLA.0b013e31825b6cb1.CrossRefPubMed
18.
Han KS, Jung DC, Choi HJ, Jeong MS, Cho KS, Joung JY, Seo HK, Lee KH, Chung J: Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer. 2010, 116 (10): 2332-42.PubMed
19.
Linder S, Blåsjö M, von Rosen A, Parrado C, Falkmer UG, Falkmer S: Pattern of distribution and prognostic value of angiogenesis in pancreatic duct carcinoma: a semiquantitative immunohistochemical study of 45 patients. Pancreas. 2001, 22 (3): 240-7. 10.1097/00006676-200104000-00003.CrossRefPubMed
20.
Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, de la Taille A, Katz AE, Olsson CA, Ennis RD: Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology. 1999, 53 (3): 542-7. 10.1016/S0090-4295(98)00561-5.CrossRefPubMed
21.
Kato T, Steers G, Campo L, Roberts H, Leek RD, Turley H, Kimura T, Kameoka S, Nishikawa T, Kobayashi M, Harris AL, Gatter KC, Pezzella F: Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer. Br J Cancer. 2007, 97 (9): 1277-86. 10.1038/sj.bjc.6604015.CrossRefPubMedPubMedCentral
22.
Medetoglu B, Gunluoglu MZ, Demir A, Melek H, Buyukpinarbasili N, Fener N, Dincer SI: Tumor angiogenesis in predicting the survival of patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2010, 140 (5): 996-1000. 10.1016/j.jtcvs.2010.07.002.CrossRefPubMed
23.
Lorusso G, Rüegg C: The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008, 130 (6): 1091-103. 10.1007/s00418-008-0530-8.CrossRefPubMed
24.
Nasr Z, Pelletier J: Tumor progression and metastasis: role of translational deregulation. Anticancer Res. 2012, 32 (8): 3077-84.PubMed
25.
McDonnell CO, Hill AD, McNamara DA, Walsh TN, Bouchier-Hayes DJ: Tumour micrometastases: the influence of angiogenesis. Eur J Surg Oncol. 2000, 26 (2): 105-15. 10.1053/ejso.1999.0753.CrossRefPubMed
26.
Tung KH, Lin CW, Kuo CC, Li LT, Kuo YH, Lin CW, Wu HC: CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling. Cancer Lett. 2012, doi:10.1016/j.canlet.2012.12.001. [Epub ahead of print]
27.
Li JY, Zhang Y, Zhang WH, Jia S, Kang Y, Zhu XY: Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. Asian Pac J Cancer Prev. 2012, 13 (5): 1901-6. 10.7314/APJCP.2012.13.5.1901.CrossRefPubMed
Metadata
Title
Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer
Authors
Jianyi Li
Yang Zhang
Wenhai Zhang
Yang Gao
Shi Jia
Jiao Guo
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-672

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Bimodal mortality dynamics for uveal melanoma: a cue for metastasis development traits?

Research article

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

Research article

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling

Research article

Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer

Research article

Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer

Research article

A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits